Trials / Completed
CompletedNCT00494442
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
Timeline
- Start date
- 2007-06-11
- Primary completion
- 2009-03-17
- Completion
- 2017-07-20
- First posted
- 2007-06-29
- Last updated
- 2018-08-01
- Results posted
- 2015-01-26
Locations
11 sites across 5 countries: United States, Australia, Germany, Spain, Sweden
Source: ClinicalTrials.gov record NCT00494442. Inclusion in this directory is not an endorsement.